Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07921188
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PF-07921188 (also known as BNT167) is a modified RNA (modRNA) vaccine candidate being co-developed by Pfizer and BioNTech for the prevention of shingles (herpes zoster) in healthy adults. The vaccine utilizes BioNTech's proprietary mRNA technology to encode specific antigens of the Varicella Zoster Virus (VZV), aiming to stimulate a potent and durable immune response, including both humoral (neutralizing antibodies) and cellular (T-cell) immunity. By leveraging the mRNA platform, the vaccine is designed to potentially offer improved tolerability and manufacturing scalability compared to existing recombinant protein-based shingles vaccines. It is currently being evaluated in Phase 1/2 clinical trials to determine the optimal dose level, formulation, and schedule for preventing viral reactivation in older adults.
- Other names
- VZV modRNA vaccineVaricella Zoster Virus modRNA vaccine
Beyond the preview
Go deeper on PF-07921188.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07921188.